Warning: The NCBI web site requires JavaScript to function. more...
Questcor Pharmaceuticals Inc, 3260 Whipple Road, Union City, CA 94587-1217, USA. gwitherell@questcor.com
Acambis and Berna are developing HolaVax-Typhoid, a single-dose, live attenuated oral vaccine for the potential prophylaxis of typhoid. A phase II trial was successfully completed in January 1999, and in September 2002, Acambis announced that a bridging trial was planned for the first half of 2003 to confirm that the vaccine produced by Berna was equivalent to the typhoid vaccine that had been studied previously.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on